Correspondence: Hideyuki Saito, PhD, Department of Pharmacy, Kumamoto University Hospital, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan. Email: [email protected]Search for more papers by this author

Kazuaki Taguchi,

Kazuaki Taguchi

Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan

Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan

Search for more papers by this author

Masahiko Kouroki,

Masahiko Kouroki

Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

Search for more papers by this author

Takafumi Ohmura,

Takafumi Ohmura

Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan

Search for more papers by this author

Hirofumi Jono,

Hirofumi Jono

Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan

Department of Clinical and Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan

Search for more papers by this author

Fumio Endo,

Fumio Endo

Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

Search for more papers by this author

Hideyuki Saito,

Corresponding Author

Hideyuki Saito

Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan

Department of Clinical and Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan

First published: 24 September 2014

https://doi.org/10.1111/ped.12382

Citations: 12

Share a link

Email
Wechat
Bluesky

Abstract

Imatinib mesylate, a selective tyrosine kinase inhibitor, is the frontline therapeutic agent used for the treatment of chronic myeloid leukemia (CML), and its therapeutic efficacy is associated with trough concentrations. Therefore, monitoring imatinib trough concentrations is strongly recommended for successful treatment of CML patients. It has been recently shown that some drugs altered imatinib plasma levels in adult patients. However, drug interactions with imatinib in children are still unknown. Here, we report a case of a 12-year-old child with epilepsy who was also diagnosed with CML and given imatinib in addition to an enzyme-inducing antiepileptic drug, carbamazepine. Compared to population kinetics data, the data obtained for the patient showed a significant decrease of imatinib plasma concentrations. Our findings suggest that monitoring imatinib plasma concentrations in children receiving enzyme-inducing antiepileptic drugs is needed to optimize the therapeutic efficacy of imatinib.

References

1Breccia M, Alimena G. How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages. Cancer Lett. 2012; 322: 127–132.
10.1016/j.canlet.2012.03.021
CAS Web of Science® Google Scholar
2Picard S, Titier K, Etienne G et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496–3499.
10.1182/blood-2006-07-036012
CAS PubMed Web of Science® Google Scholar
3Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996; 2: 561–566.
10.1038/nm0596-561
CAS PubMed Web of Science® Google Scholar
4Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet. 2005; 44: 879–894.
10.2165/00003088-200544090-00001
CAS PubMed Web of Science® Google Scholar
5Peng B, Hayes M, Resta D et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol. 2004; 22: 935–942.
10.1200/JCO.2004.03.050
CAS PubMed Web of Science® Google Scholar
6Wen PY, Yung WK, Lamborn KR et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin. Cancer Res. 2006; 12: 4899–4907.
10.1158/1078-0432.CCR-06-0773
CAS PubMed Web of Science® Google Scholar
7Pursche S, Schleyer E, von Bonin M et al. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr. Clin. Pharmacol. 2008; 3: 198–203.
10.2174/157488408785747656
CAS PubMed Google Scholar
8Champagne MA, Capdeville R, Krailo M et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 2004; 104: 2655–2660.
10.1182/blood-2003-09-3032
CAS PubMed Web of Science® Google Scholar
9Yamakawa Y, Hamada A, Shuto T et al. Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia. Clin. Pharmacol. Ther. 2011; 90: 157–163.
10.1038/clpt.2011.102
CAS PubMed Web of Science® Google Scholar
10Petain A, Kattygnarath D, Azard J et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin. Cancer Res. 2008; 14: 7102–7109.
10.1158/1078-0432.CCR-08-0950
CAS PubMed Web of Science® Google Scholar
11Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 2003; 349: 1423–1432.
10.1056/NEJMoa030513
CAS PubMed Web of Science® Google Scholar
12Champagne MA, Fu CH, Chang M et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatr. Blood Cancer 2011; 57: 56–62.
10.1002/pbc.23031
PubMed Web of Science® Google Scholar
13Bolton AE, Peng B, Hubert M et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother. Pharmacol. 2004; 53: 102–106.
10.1007/s00280-003-0722-9
CAS PubMed Web of Science® Google Scholar
14Reardon DA, Egorin MJ, Quinn JA et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol. 2005; 23: 9359–9368.
10.1200/JCO.2005.03.2185
CAS PubMed Web of Science® Google Scholar
15Reardon DA, Desjardins A, Vredenburgh JJ et al. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer 2012; 118: 4759–4767.
10.1002/cncr.26541
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume56, Issue4

August 2014

Pages e33-e36

Carbamazepine–imatinib interaction in a child with chronic myeloid leukemia

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Carbamazepine–imatinib interaction in a child with chronic myeloid leukemia

Abstract

References

Citing Literature

References

Related

Information